Based on the OI percentage, 60 stocks were on the short-covering list. These included Alkem Laboratories, IndusInd Bank, United Breweries, Dr Lal PathLabs and Aarti Industries.

Trade setup for Thursday: Top 15 things to know before the opening bell

Jefferies maintained an underperform rating on Hindustan Petroleum Corporation Limited (HPCL) citing weak marketing and transitory refining weakness. CLSA retained a buy rating on Manappuram Finance as yields fell but growth became visible. Credit Suisse upheld an underperform rating on Dr Lal Pathl…

Hot Stocks: Brokerages on HPCL, Manappuram Finance, Dr Lal Pathlabs and Lupin

Dr Lal Pathlabs reports a weak set of Q4FY23 numbers. The stock is buzzing in trade after positive commentary from the management. In our special segment Insight Edge, Ekta Batra gets us the key takeaways.

#drlalpathlabs  #Q4FY23results #Q4FY3earnings #cnbctv18 #businessnews #businessnewstoday  #businessnewsinenglish #sharemarkettoday 

About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here. 

You can also connect with CNBC-TV18 News Online
Catch the latest news: https://bit.ly/2YbpXBM

Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/

Stay updated with all the market action in real time: https://www.cnbctv18.com/market-live/

You can also stay updated with all the latest news on-the-go with CNBC-TV18 Minis: https://www.cnbctv18.com/minis/

Subscribe to our Channel: https://bit.ly/3nvEcxf

Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News
Follow us on Instagram: https://www.instagram.com/cnbctv18india/
Catch us on: Linkedin: https://in.linkedin.com/company/cnbc-tv18
n18oc_business

Insight Edge: Dr Lal Pathlabs Buzzing In Trade After Reports Weak Set Of Q4 Numbers | CNBC-TV18

Dr Lal PathLabs MD Om Manchanda says margins have improved; expects them to be in 'this' range for FY24. 

Read: https://bit.ly/456wCy3

--------------------------------------------------------------------------------------------------------------------
For more videos subscribe to our channel: http://bit.ly/32JXa74
Visit BQ Prime for more news: https://www.bqprime.com/
Don't enter the stock market unaware. Read all Research Reports here: https://www.bqprime.com/research-reports

For the latest business news and analysis
Subscribe to our Newsletters here: https://www.bqprime.com/my-bq/newsletter
Subscribe to our Telegram channel: https://t.me/BQPrime

Follow BQ Prime here
Twitter: https://twitter.com/bqprime
Facebook: https://www.facebook.com/BQPrime/
LinkedIn: https://www.linkedin.com/company/13184554/
Instagram: https://www.instagram.com/bqprime/
Pinterest: https://in.pinterest.com/BQPrimeNews/

Dr Lal PathLabs' Om Manchanda On Margins | BQ Prime

Now you would remember that in FY21-22 we had the Omicron and the Delta wave coming in. So, what you are seeing this year as a minus 5% is really not minus 5. It is a total patient because of large COVID base of the previous year

We continue to invest in building labs, infrastructure to have sustainable growth profile: Bharath Uppiliappan, Dr Lal Pathlabs

Excluding Suburban, implied non Covid sales up 7.5% YoY on what was a weak base of Rs 4.2 billion last year

Dr. Lal Pathlabs Q4 Results Review - Caution Warranted On Volume Growth: Yes Securities

Dr Lal PathLabs Ltd reported 8.2 percent year on year decline in net profit for the March quarter to Rs 57 crore from Rs 62 crore. Revenue rose just 1.1 percent to Rs 491 crore from a year ago.

Dr Lal PathLabs stock under pressure after March quarter earnings fails to impress

Revenue from operations rose to Rs 491 crore for the fourth quarter as compared with Rs 485 crore in the year-ago period, Dr Lal PathLabs said in a regulatory filing.

Dr Lal PathLabs Q4 net profit falls 8% to Rs 57 crore

Dr Lal PathLabs on Thursday said its consolidated profit after tax declined 8 per cent to Rs 57 crore for the fourth quarter ended March 31, 2023.

Dr Lal PathLabs Q4 net profit falls 8 pc to Rs 57 crore | The Financial Express

Dr. Lal PathLabs Ltd on Thursday reported a sixth consecutive fall in quarterly profit as a continued slide in income from Covid-related testing outpaced growth in its core business

Dr Lal PathLabs reports decline in profit for quarter ending March

Dr Lal PathLabs Q4 result: On the operating front, earnings before interest, taxes, depreciation and amortization) decreased by 4.5 percent to Rs 115.6 crore

Dr Lal PathLabs Q4 result: Net profit falls 7.5% to Rs 57 crore

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator. 